Phase 2Completed

A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia

A Phase Ⅱ Randomized, Parallel-group, Placebo-controlled, Active-controlled Trial to Assess the Efficacy, Safety of the SYH2053 Subcutaneous Injection in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia

Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (Industry)
Enrollment
156 enrolled
Conditions
Hypercholesterolemia and Mixed Hyperlipidemia
Interventions
SYH2053/placebo injection; Inclisiran (Leqvio®) 300mg
Ages
adults, older adults
Registry
NCT07421232

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to compare the effectiveness, safety of SYH2053 in Participants with primary hypercholesterolemia or mixed dyslipidemia. A total of 156 Participants were actually enrolled

Primary outcomes

  • Percentage change in LDL-C relative to baseline

History

  1. Registered

  2. Study completion

  3. Primary completion

  4. Started